Intravenous cyclophosphamide<i>vs</i>rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial

Sircar, Geetabali; Prosad Goswami, Rudra; Sircar, Dipankar; Ghosh, Alakendu; Ghosh, Parasar

doi:10.1093/rheumatology/key213

Public

Intravenous cyclophosphamidevsrituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial

Published in Lara D. Veeken • Jun 26, 2018

Authors:

Geetabali Sircar

Rudra Prosad Goswami

Dipankar Sircar

Abstract

Objectives: SSc is characterized by fibrotic changes in the skin and lung, and the mainstay of treatment has been CYC. B cell involvement suggests that rituximab (RTX) may also be of therapeutic benefit. The aim of the study was to compare the efficacy and safety of RTX compared with CYC in retardin...

Subject

Medicine

Rituximab

Scleroderma (fungus)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!